Spatial Patterns in Prostate Cancer-specific Mortality in Pennsylvania Using Pennsylvania Cancer Registry Data, 2004-2014

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 May 8

PMID 32375682

Citations 2

Authors

Ming Wang

Emily Wasserman

Nathaniel Geyer

Rachel M Carroll

Shanshan Zhao

Lijun Zhang

Raymond Hohl

Eugene J Lengerich

Alicia C McDonald

Affiliations

Soon will be listed here.

Abstract

Background: Spatial heterogeneity of prostate cancer-specific mortality in Pennsylvania remains unclear. We utilized advanced geospatial survival regressions to examine spatial variation of prostate cancer-specific mortality in PA and evaluate potential effects of individual- and county-level risk factors.

Methods: Prostate cancer cases, aged ≥40 years, were identified in the 2004-2014 Pennsylvania Cancer Registry. The 2018 County Health Rankings data and the 2014 U.S. Environmental Protection Agency's Environmental Quality Index were used to extract county-level data. The accelerated failure time models with spatial frailties for geographical correlations were used to assess prostate cancer-specific mortality rates for Pennsylvania and by the Penn State Cancer Institute (PSCI) 28-county catchment area. Secondary assessment based on estimated spatial frailties was conducted to identify potential health and environmental risk factors for mortality.

Results: There were 94,274 cases included. The 5-year survival rate in PA was 82% (95% confidence interval, CI: 81.1-82.8%), with the catchment area having a lower survival rate 81% (95% CI: 79.5-82.6%) compared to the non-catchment area rate of 82.3% (95% CI: 81.4-83.2%). Black men, uninsured, more aggressive prostate cancer, rural and urban Appalachia, positive lymph nodes, and no definitive treatment were associated with lower survival. Several county-level health (i.e., poor physical activity) and environmental factors in air and land (i.e., defoliate chemical applied) were associated with higher mortality rates.

Conclusions: Spatial variations in prostate cancer-specific mortality rates exist in Pennsylvania with a higher risk in the PSCI's catchment area, in particular, rural-Appalachia. County-level health and environmental factors may contribute to spatial heterogeneity in prostate cancer-specific mortality.

Citing Articles

Spatial-temporal Bayesian accelerated failure time models for survival endpoints with applications to prostate cancer registry data.

Wang M, Li Z, Lu J, Zhang L, Li Y, Zhang L BMC Med Res Methodol. 2024; 24(1):86.

PMID: 38589783 PMC: 11003030. DOI: 10.1186/s12874-024-02201-w.

Spatio-temporal mapping of breast and prostate cancers in South Iran from 2014 to 2017.

Montazeri M, Hoseini B, Firouraghi N, Kiani F, Raouf-Mobini H, Biabangard A BMC Cancer. 2020; 20(1):1170.

PMID: 33256668 PMC: 7708260. DOI: 10.1186/s12885-020-07674-8.

References

Fairley L, Forman D, West R, Manda S . Spatial variation in prostate cancer survival in the Northern and Yorkshire region of England using Bayesian relative survival smoothing. Br J Cancer. 2008; 99(11):1786-93. PMC: 2600701. DOI: 10.1038/sj.bjc.6604757. View

Wang M, Matthews S, Iskandarani K, Li Y, Li Z, Chinchilli V . Spatial-temporal analysis of prostate cancer incidence from the Pennsylvania Cancer Registry, 2000-2011. Geospat Health. 2017; 12(2):611. PMC: 6337722. DOI: 10.4081/gh.2017.611. View

Carroll R, Lawson A, Jackson C, Zhao S . Assessment of spatial variation in breast cancer-specific mortality using Louisiana SEER data. Soc Sci Med. 2017; 193:1-7. PMC: 5659900. DOI: 10.1016/j.socscimed.2017.09.045. View

Carroll R, Zhao S . Trends in Colorectal Cancer Incidence and Survival in Iowa SEER Data: The Timing of It All. Clin Colorectal Cancer. 2019; 18(2):e261-e274. PMC: 7983285. DOI: 10.1016/j.clcc.2018.12.001. View

Lee J, Giovannucci E, Jeon J . Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus. 2016; 5(1):1548. PMC: 5021649. DOI: 10.1186/s40064-016-3233-y. View

Hood C, Gennuso K, Swain G, Catlin B . County Health Rankings: Relationships Between Determinant Factors and Health Outcomes. Am J Prev Med. 2015; 50(2):129-35. DOI: 10.1016/j.amepre.2015.08.024. View

Lynch S, Mitra N, Ross M, Newcomb C, Dailey K, Jackson T . A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness. PLoS One. 2017; 12(3):e0174548. PMC: 5367705. DOI: 10.1371/journal.pone.0174548. View

Zahnd W, James A, Jenkins W, Izadi S, Fogleman A, Steward D . Rural-Urban Differences in Cancer Incidence and Trends in the United States. Cancer Epidemiol Biomarkers Prev. 2017; 27(11):1265-1274. PMC: 5787045. DOI: 10.1158/1055-9965.EPI-17-0430. View

Weiner A, Matulewicz R, Eggener S, Schaeffer E . Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016; 19(4):395-397. DOI: 10.1038/pcan.2016.30. View

10.

Dottino J, He W, Sun C, Zhao H, Fu S, Lu K . Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol. 2019; 154(2):405-410. PMC: 6810571. DOI: 10.1016/j.ygyno.2019.06.003. View

11.

Swindell W . Accelerated failure time models provide a useful statistical framework for aging research. Exp Gerontol. 2008; 44(3):190-200. PMC: 2718836. DOI: 10.1016/j.exger.2008.10.005. View

12.

Moyer V . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-34. DOI: 10.7326/0003-4819-157-2-201207170-00459. View

13.

Wilson R, Ryerson A, Singh S, King J . Cancer Incidence in Appalachia, 2004-2011. Cancer Epidemiol Biomarkers Prev. 2016; 25(2):250-8. PMC: 6317710. DOI: 10.1158/1055-9965.EPI-15-0946. View

14.

Vanderpool R, Huang B . Cancer risk perceptions, beliefs, and physician avoidance in Appalachia: results from the 2008 HINTS Survey. J Health Commun. 2010; 15 Suppl 3:78-91. DOI: 10.1080/10810730.2010.522696. View

15.

Sharp G, Lee B . New Faces in Rural Places: Patterns and Sources of Nonmetropolitan Ethnoracial Diversity Since 1990. Rural Sociol. 2018; 82(3):411-443. PMC: 5856471. DOI: 10.1111/ruso.12141. View

16.

Messer L, Jagai J, Rappazzo K, Lobdell D . Construction of an environmental quality index for public health research. Environ Health. 2014; 13(1):39. PMC: 4046025. DOI: 10.1186/1476-069X-13-39. View

17.

Khan S, Cai J, Nielsen M, Troester M, Mohler J, Fontham E . The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC. Prostate. 2017; 77(8):878-887. PMC: 5695861. DOI: 10.1002/pros.23342. View

18.

Bonn S, Sjolander A, Trolle Lagerros Y, Wiklund F, Stattin P, Holmberg E . Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014; 24(1):57-64. DOI: 10.1158/1055-9965.EPI-14-0707. View

19.

Lewis-Mikhael A, Olmedo-Requena R, Martinez-Ruiz V, Bueno-Cavanillas A, Jimenez-Moleon J . Organochlorine pesticides and prostate cancer, Is there an association? A meta-analysis of epidemiological evidence. Cancer Causes Control. 2015; 26(10):1375-92. DOI: 10.1007/s10552-015-0643-z. View

20.

Pollack C, Armstrong K, Mitra N, Chen X, Ward K, Radhakrishnan A . A multidimensional view of racial differences in access to prostate cancer care. Cancer. 2017; 123(22):4449-4457. PMC: 5673580. DOI: 10.1002/cncr.30894. View